KalVista Pharmaceuticals Inc Stock News

May 03, 2020 (CDN Newswire via Comtex) -- A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...

Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According

Bank of New York Mellon Corp trimmed its position in Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exch

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals ( KALV – Research Report ) today and set a price target of $28.00 . The company’s shares closed last Wednesday at

Their low debt-equity ratio reduces the investment risk Continue reading...

Wall Street Recommends Buying These 2 Falling Knives, Stocks: STML,KALV, release date:Apr 13, 2020

Wall Street Recommends Buying These 2 Falliing Knives, Stocks: STML,KALV, release date:Apr 13, 2020

Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to

Franklin Resources Inc. acquired a new position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commis

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc

Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announce

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...